MacroGenics Inc.'s positive Phase III SOPHIA study sets its margetuximab up for a role in treating third-line-plus HER2-positive metastatic breast cancer (mBC) with potential to expand to earlier lines and other cancers. It also bodes well for the company's antibody engineering platform.
MacroGenics reported on Feb. 6, to great fanfare, positive progression-free survival (PFS) data in SOPHIA, which tested margetuximab with chemo...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)